MRTX0902 is an investigational small molecule designed to target specific mutant forms of the KRAS protein, which are commonly found in various cancers. It is being developed primarily for the treatment of non-small cell lung cancer (NSCLC) and other solid tumors that harbor KRAS G12C mutations. The compound works by selectively binding to the inactive form of the KRAS G12C protein, locking it in an off state and preventing it from driving uncontrolled cell growth. This targeted mechanism allows for potent inhibition of tumor signaling pathways, particularly the MAPK pathway, leading to reduced tumor proliferation and potential tumor regression in preclinical models. MRTX0902 is currently undergoing clinical evaluation to assess its safety, pharmacokinetics, and efficacy in patients with advanced cancers who have limited treatment options. Its development represents a promising approach in precision oncology, aiming to improve outcomes for patients with KRAS-driven tumors.